Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 17 of 17 for “"steatotic liver disease"”.
-
Targeting LGALS3 to treat steatotic liver disease and hepatocarcinogenesis
Non-alcoholic fatty liver disease (NAFLD), recently renamed as Metabolic dysfunction-associated steatotic liver disease (MASLD), is the leading cause of chronic liver disease (CLD) and liver-related morbidity and mortality worldwide. NAFLD, characterized by hepatic fat accumulation and coexisting …
-
Predicting Progression of Metabolic Dysfunction-associated Steatotic Liver Disease
… from metabolic dysfunction-associated fatty liver to metabolic dysfunction-associated steatohepatitis, a more serious prognosis that can lead to liver failure and death. Additional adverse progressed outcomes include hepatic failure, fibrosis, cirrhosis, and malignant neoplasm of liver and …
-
Modulation of Hepatic Lipid Metabolism by Dietary Fats in Neonatal Pigs: Implications for Steatotic Liver Disease
Steatotic liver disease (SLD) is increasingly recognized in pediatric populations, yet its nutritional origins and development are poorly understood. Using a neonatal pig model, we conducted three nutritional based studies to evaluate how dietary lipid composition influences the onset, progression, …
-
NON-INVASIVE METHODS TO PREDICT AND MONITORING METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE BY USING ULTRASOUND IMAGING
Metabolic-Associated Steatotic Liver Disease (MASLD) is becoming increasingly critical due to its rising global prevalence and its potential to progress to more severe liver diseases, such as Metabolic-Associated Steatohepatitis (MASH), fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). The …
-
Impact of mtDNA Signature on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Progression and Cardiometabolic Outcomes in Mice
Cardiometabolic diseases (CMDs) are a major global health burden, with metabolic dysfunction-associated steatotic liver disease (MASLD) emerging as both a prevalent comorbidity and an independent risk factor for adverse outcomes. While diet and lifestyle are established contributors, variation in …
-
Účinek agonistů nukleárních receptorů (FXR, CAR, aj.) na játra a hepatocyty za různých stavů
… receptor agonists (e.g., FXR, CAR) on the liver and hepatocytes in vivo and in vitro across diverse physiological and pathological conditions Metabolic dysfunction-associated steatotic liver disease (MASLD) affects a substantial proportion of the global population, while currently available …
-
SDOH, GLP-1 Prescription Patterns and MASLD-associated Liver Disease in a Real World Population
… medical center to examine predictors of advanced liver disease and GLP-1 RA receptor agonist use among a cross-sectional study of adults with metabolic dysfunction–associated steatotic liver disease (MASLD) and related conditions. Variables included diagnoses, prescriptions, demographics, BMI, …
-
Υπολογισμός του επιπολασμού της μεταβολικά σχετιζόμενης στεατωτικής νόσου του ήπατος σε άτομα με σακχαρώδη διαβήτη τύπου 2
… του ήπατος (metabolic dysfunction-associated steatotic liver disease, MASLD) αποτελεί μία από τις συχνότερες χρόνιες ηπατικές νόσους παγκοσμίως και εμφανίζει ιδιαίτερα αυξημένο επιπολασμό σε άτομα με σακχαρώδη διαβήτη τύπου 2. Η στενή σχέση της με την ινσουλινοαντίσταση, την παχυσαρκία και το …
-
PNPLA3 P.I148M VARIANT INCREASES LIPID DROPLETS NUMBER AND SIZE IN PATIENT-DERIVED LIVER ORGANOIDS
… main genetic determinant of metabolic associated steatotic liver disease (MASLD). To this day, this association still lacks a molecular characterization, due to the lack of comprehensive human models. To overcome this gap in knowledge, we generated patient-derived human liver organoids (HLOs) and …
-
Epigenetic therapy based on micrornas inhibition for the amelioration of masld phenotype
Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently the most prevalent liver disorder worldwide. In Europe, around 25% of people suffer from this disease. It is strongly associated with several comorbidities, including obesity, type 2 diabetes mellitus, and metabolic …
-
Συσχέτιση της προσκόλλησης στη μεσογειακή δίαιτα με δείκτες φλεγμονής σε δείγμα παιδιών και εφήβων με παχυσαρκία και μεταβολικά σχετιζόμενη στεατωτική νόσο του ήπατος
… νόσος του ήπατος (Metabolic Associated Steatotic Liver Disease, MASLD) αποτελεί τη συχνότερη αιτία χρόνιας ηπατικής νόσου στον παιδικό πληθυσμό, επηρεάζοντας το 5,5-10% των παιδιών παγκοσμίως, με το ποσοστό να ανέρχεται στο 34% στα παιδιά με παχυσαρκία. Η φλεγμονή διαδραματίζει βασικό …
-
Epithelial cell plasticity in chronic liver disease (MASLD/NAFLD)
It has been proposed that liver regeneration in chronic liver disease, such as metabolic dysfunction-associated steatotic liver disease, previously known as non-alcoholic fatty liver disease, is driven by hepatocyte renewal in the early stages, but when hepatocyte proliferation is impaired due to …
-
Dipeptidyl Peptidase-4 in Cariometabolic Disease
… models of metabolic dysfunction-associated steatotic liver disease (MASLD), cardiometabolic disease and myocardial infarction. In vivo experiments were conducted using several genetic models, including systemic Dpp4 knockout mice (Dpp4-/-), hepatocyte-specific knockout mice (Dpp4hep-/-) and …
-
GENOME-WIDE ASSOCIATION STUDY OF NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS IN MASLD: EVIDENCE FROM AN ITALIAN POPULATION
Metabolic Associated Steatotic Liver Disease (MASLD) is the most prevalent cause of chronic liver disease worldwide and a significant risk factor for cirrhosis and hepatocellular carcinoma (HCC). Despite its pathogenesis being determined by both environmental and genetic determinants, the genetic …
-
SARCOPENIA, LIVER AND CARDIOVASCULAR ALTERATIONS IN A MULTICENTRIC COHORT OF PATIENTS WITH MASLD: EVALUATION OF CLINICAL PRESENTATION AND GENETIC PREDISPOSITION
… condition but is also associated with several diseases, including chronic liver disease (CLD) and cardiovascular (CV) disease. Metabolic-dysfunction associated steatotic liver disease (MASLD) is defined by the presence of liver steatosis combined with, at least, one cardiometabolic risk factor, …
-
UNVEILING THE ADVERSE EFFECTS OF POLYSTYRENE NANOPLASTICS IN THE HUMAN-DERIVED HEPG2-OA STEATOTIC-LIKE MODEL, VALIDATING DYSFUNCTIONAL HUMAN-DERIVED SW872 ADIPOCYTE IN VITRO MODELS FOR THE STUDY OF CARDIOMETABOLIC DISEASES, AND ASSESSING TRIMETHYLAMINE N-OXIDE IN A PLIC STUDY SUB-COHORT
Contesto e obiettivi. Le malattie cardiometaboliche (CM) e cardiovascolari (CV) rappresentano attualmente la principale causa di mortalità a livello mondiale. Negli ultimi anni, i progressi della ricerca hanno fatto luce su nuovi potenziali fattori di rischio, coinvolti sia nelle CMD che nelle …